.png){kind=icon}
返回
Gene Therapy for Blindness
.png){kind=icon}
PRE
AI
DOI：10.1146/annurev-neuro-062012-170304.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Sight-restoring therapy for the visually impaired and blind is a major unmetmedical need. Ocular gene therapy is a rational choice for restoring vision or preventing the loss of vision because most blinding diseases originate in cellular components of the eye, a compartment that is optimally suited for the delivery of genes, and many of these diseases have a genetic origin or genetic component. In recent years we have witnessed major advances in the field of ocular gene therapy, and proof-of-concept studies are under way to evaluate the safety and efficacy of human gene therapies. Here we discuss the concepts and recent advances in gene therapy in the retina. Our review discusses traditional approaches such as gene replacement and neuroprotection and also new avenues such as optogenetic therapies. We conjecture that advances in gene therapy in the retina will pave the way for gene therapies in other parts of the brain.
Keyword:
eye
retina
optogenetics
virus
gene replacement
neuroprotection
期刊
IF:
13.2
论文数:
930
被引数:
1.3W
机构
引用论文
Angiotensin stimulates bicarbonate transport and Na+/K+ ATPase in rat proximal straight tubules.
OAAI
.png){kind=icon}
OAAI分享收藏Rod-Derived Cone Viability Factor for Treating Blinding Diseases: From Clinic to Redox Signaling
OAAI
OAAI分享收藏分享收藏
查看更多内容